H. Lundbeck A/S Company Profile

01:03 EST 25th November 2017 | BioPortfolio

We are a research-based company. We engage in research to find new drugs for treatment of CNS disorders, includ­ing depression, schizophrenia, Alzheimer’s disease and Parkinson’s disease.These are serious disorders. They affect not only patients, but also their families and friends. Besides the stress of having a CNS disorder, patients are often exposed to prejudice because, in many sections of society, there is still far too little understanding of how adversely a CNS disorder affects an individual’s life.
We have taken upon ourselves the task of improving quality of life for persons with a psychiatric or neurological disorder, and we are working intensely to find and develop new and improved drugs. We believe that we can make a significant difference, and we are happy to do so in cooperation with others.


Ottiliavej 9


Phone: 45 36 30 13 11
Fax: 45 36 30 19 40

News Articles [71 Associated News Articles listed on BioPortfolio]

H. Lundbeck A/S: Lundbeck increases its share capital by 470,889 shares (0.2373 % of outstanding shares) as a result of exercise of employee warrants

Valby, Denmark, 2017-08-22 10:47 CEST (GLOBE NEWSWIRE) -- Valby, Denmark, 22 August 2017 - H. Lundbeck A/S (Lundbeck) today announced that it has decided to increase its share capital by DKK 2,354,...

H. Lundbeck A/S: Lundbeck increases its share capital by 116,330 shares (0.0585 % of outstanding shares) as a result of exercise of employee warrants

Valby, Denmark, 2017-11-21 11:28 CET (GLOBE NEWSWIRE) -- Valby, Denmark, 21 November 2017 - H. Lundbeck A/S (Lundbeck) today announced that it has decided to increase its share capital by DKK 581,6...

H. Lundbeck A/S: Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

Valby, Denmark, 2017-11-17 18:55 CET (GLOBE NEWSWIRE) -- Valby, Denmark, 17 November 2017 - H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by executives and persons close...

H. Lundbeck A/S: Changes to Lundbeck's Executive Management

Valby, Denmark, 2017-10-30 20:48 CET (GLOBE NEWSWIRE) -- Valby, Denmark, 30 October 2017 - H. Lundbeck A/S (Lundbeck) today announced changes to its Executive Management team. Following the resigna...

H. Lundbeck-Aktie: Abgang zweier Top-Manager sorgt für Kurssturz - Aktienanalyse

Schwarzach am Main - H. Lundbeck-Aktienanalyse von "ZertifikateJournal": Kare Schultz wechselt von H. Lundbeck (ISIN: DK0010287234, WKN: 922351, Ticker-Symbol: LDB, Nasdaq OTC-Symbol: HLUKF) zu TEV...

Teva poaches Lundbeck's Schultz as new CEO

Shares in Lundbeck fall as two senior posts become vacant

US nod for injectable bipolar drug a welcome boost for Lundbeck

Danish CNS specialist Lundbeck and Japan’s Otsuka Pharmaceutical have announced that Abilify Maintena…

Lundbeck plunges as Teva poaches its CEO

Danish CNS specialist Lundbeck saw its shares drop 11.58% to 364.20 Danish kroner this morning, when…

Drugs and Medications [14 Associated Drugs and Medications listed on BioPortfolio]

Neoprofen [Lundbeck Inc.]

These highlights do not include all the information needed to use NeoProfen safely and effectively. See full prescribing information for NeoProfen. NeoProfen (ibuprofen lysine) Injection for intraveno...

Panhematin [Lundbeck Inc.]

Panhematin Hemin For Injection Rx only For intravenous infusion only.

Atryn [Lundbeck Inc.]

These highlights do not include all the information needed to use ATryn safely and effectively. See full prescribing information for ATryn. ATryn, Antithrombin (Recombinant) Lyophilized powder for rec...

Peganone [Lundbeck Inc.]

PEGANONE 250 mg Tablets (ethotoin tablets, USP) R Only

Cogentin [Lundbeck Inc.]

Cogentin® (benztropine mesylate injection) Rx only

PubMed Articles [0 Results]


Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson Disease

The purpose of this study is to investigate the utility of dopamine transporter imaging in monitoring and predicting the progression of Parkinson disease. This study will be performed in ...

Companies [16 Associated Companies listed on BioPortfolio]

Lundbeck LLC

Lundbeck in the U.S., headquartered in Deerfield, Illinois, is a wholly-owned subsidiary of H. Lundbeck A/S in Denmark. Lundbeck is committed to accelerating advances in brain dis...

Lundbeck Inc.

Lundbeck Inc. was established in March 2009 following the acquisition of Ovation Pharmaceuticals, Inc. by Lundbeck and has proven success in developing and commercializing high-ne...


Depression, schizophrenia, Alzheimer's, Parkinson's, epilepsy, Multiple Sclerosis, and migraines have their foundation in the Central Nervous System - our key focus areas. Lundbeck's entire R&D effort...


The Lundbeck Institute is pleased to present Psychotropics Online, a comprehensive guide to CNS compounds and products.We have published Psychotropics since the 1960s in a printed handbook version, an...

Lundbeck Limited

As a pharmaceutical manufacturer, Lundbeck is unique in that we focus solely on the treatment of diseases of the central nervous system. Our aim is to be the world leader in the development of pharmac...

More Information about "H. Lundbeck A/S" on BioPortfolio

We have published hundreds of H. Lundbeck A/S news stories on BioPortfolio along with dozens of H. Lundbeck A/S Clinical Trials and PubMed Articles about H. Lundbeck A/S for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of H. Lundbeck A/S Companies in our database. You can also find out about relevant H. Lundbeck A/S Drugs and Medications on this site too.

Quick Search

Relevant Topics

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Psychiatry is the study of mental disorders and their diagnosis, management and prevention.  Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...

Schizophrenia is a common  serious long-term mental health condition that affects 5 in 1000 in the UK. It causes a range of different psychological symptoms; hallucinations, delusions, muddled thoughts based on the hallucinations or delusions and ch...

Corporate Database Quicklinks

Searches Linking to this Company Record